Therapeutic area intelligence for Peripheral Arterial Disease with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Everolimus →

Recent signals(2)

ClinicalJuly 6, 2026

Study on Predictors of Major Adverse Limb Events After Iliac Stenting

A real-world cohort study will evaluate predictors of major adverse limb events after endovascular iliac artery stenting.

ClinicalJuly 3, 2026

Cook Research initiates RCT for Evero DCB in PAD treatment

The Evero drug-coated balloon is being evaluated for long-term safety and effectiveness against paclitaxel DCBs in PAD.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Peripheral Arterial Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.